Kodiak Sciences Inc (KOD)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 35/100 (MEDIUM), 9.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 23.87% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update
- Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News
- Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
- Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
- Kodiak Sciences More Than Doubles on Eye Disease Trial Results
- A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
- Why Kodiak Sciences Skyrocketed Today
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Infographic: Study design for ELARA, an open-label, phase 3b trial of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration or diabetic macular edema. — Eye (Lond) 2026 Jun 5 PMID 42249143
- Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial. — JAMA Ophthalmol 2026 Jun 1 PMID 42024409
- Eye care adherence in pediatric and elderly: Understanding and addressing the challenges. — Prog Retin Eye Res 2026 May PMID 41720395
- Artificial Intelligence-based characterization of therapeutic response in fluid types and volumes influencing retinal function in neovascular age-related macular degeneration. — Sci Rep 2026 Feb 17 PMID 41703113
- Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study. — BMJ Open Ophthalmol 2026 Feb 3 PMID 41633707
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Kodiak Sciences Inc.
Full KOD Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.